Novartis Invests USD 1 Billion to Build Largest Pharmaceutical R&D Institute in China

Novartis announced a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, health reform and improving the health care of the Chinese people. The Novartis investment will include a significant expansion of The Novartis Institute of BioMedical Research (NIBR) in Shanghai.


The Novartis Campus Shanghai will focus on detecting and developing new therapies to cure diseases in Asia. The site covers a land area of 81,620m² south of the Chuan Yang River. The campus will co-locate a number of Novartis divisions and business units. There are 11 separate projects for Phase 1 with completion scheduled for 2014.


Novartis has engaged AV Helpdesk to oversee the implementation of a state-of-the-art audiovisual communications platform for the new campus. The unique architecture of the new buildings presents numerous challenges to the effective integration of communication technology. These architectural challenges, combined with the immense scope of the project, will require intensive design efforts in order to provide a variety of cutting-edge communication and collaboration tools. Providing the ability to work effectively with other research facilities around the world is paramount to the success of this project, and AV Helpdesk’s insight and experience will be essential to making it happen.